Susceptibility to invasive meningococcal disease: Polymorphism of complement system genes and neisseria meningitidis factor H binding protein

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Bradley, Declan T ^a,b   Bourke, Thomas W ^a   Fairley, Derek J ^c   Borrow, Raymond ^d,e   Shields, Michael D ^a   Zipfel, Peter F ^f,g   Hughes, Anne E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b PUBLIC HEALTH AGENCY   (United Kingdom)

^c ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f HANS KNÖLL INSTITUTE   (Germany)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN SUBFAMILY A; FACTOR H BINDING PROTEIN SUBFAMILY B; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; COMPLEMENT; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; MEMBRANE COFACTOR PROTEIN;

ADOLESCENT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CFH GENE; CHILD; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; INFANT; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PROTEIN EXPRESSION; ADULT; COMPLEMENT CLASSICAL PATHWAY; GENE LOCUS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PRESCHOOL CHILD; RECURRENT DISEASE; YOUNG ADULT;

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, BACTERIAL; ANTIGENS, CD46; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; NEISSERIA MENINGITIDIS; POLYMORPHISM, GENETIC; RECURRENCE; YOUNG ADULT;

EID: 84925874412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120757     Document Type: Article

References (44)

1. Zipfel PF. Complement and immune defense: From innate immunity to human diseases. Immunol Lett. 2009; 126:1-7. doi: 10.1016/j.imlet.2009.07.005 PMID: 19616581
2. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009; 9: 729-740. doi: 10.1038/nri2620 PMID: 19730437
3. Bradley DT, Zipfel PF, Hughes AE. Complement in age-related macular degeneration: A focus on function. Eye. 2011; 25: 683-693. doi: 10.1038/eye.2011.37 PMID: 21394116
4. Zipfel PF, Hallstrom T, Hammerschmidt S., Skerka C. The complement fitness factor H: Role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine. 2008; 26: 67-74.
5. Klein RJ, Zeiss C, Chew E.Y., Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005; 308: 385-389. PMID: 15761122
6. Haines JL, Hauser MA, Schmidt S, Scott W.K., Olson LM, Gallins P, et al. Complementfactor H variant increases the risk of age-related macular degeneration. Science. 2005; 308: 419-421. PMID: 15761120
7. Hageman GS, Anderson DH, Johnson L.V., Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplo-type in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005; 102: 7227-7232. PMID: 15870199
8. Hughes AE, Orr N, Esfandiary H., Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplo-type, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. 2006; 38:1173-1177. PMID: 16998489
9. Zipfel PF, Edey M, Heinen S., Jozsi M, Richter H, Misselwitz J., et al. Deletion of complement factor H-re-lated genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007; 3: e41. PMID: 17367211
10. Zhao J, Wu H, Khosravi M., Cui H, Qian X, Kelly J.A., et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011; 7: e1002079. doi: 10.1371/journal.pgen.1002079 PMID: 21637784
11. Davila S, Wright VJ, Khor C.C., Sim KS, Binder A, Breunis WB, et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet. 2010; 42: 772-776. doi: 10.1038/ng.640 PMID: 20694013
12. Ramsay M, Kaczmarski E, Rush M., Mallard R, Farrington P, White J. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev. 1997; 7: R49-54. PMID: 9127510
13. Madico G, Welsch JA, Lewis L.A., McNaughton A., Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006; 177: 501-510. PMID: 16785547
14. Lewis LA, Ngampasutadol J, Wallace R., Reid JEA, Vogel U, Ram S. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 2010; 6: e1001027. doi: 10.1371/journal.ppat.1001027 PMID: 20686663
15. Lewis LA, Carter M, Ram S. The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol. 2012; 188: 5063-5072. doi: 10.4049/jimmunol.1103748 PMID: 22504643
16. Dunphy KY, Beernink PT, Brogioni B, Granoff DM. Effect of factor H-binding protein sequence variation on factor H binding and survival of neisseria meningitidis in human blood. Infect Immun. 2011; 79: 353-359. doi: 10.1128/IAI.00849-10 PMID: 21041484
17. Schneider MC, Prosser BE, Caesar J.J., Kugelberg E., Li S, Zhang Q, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009; 458: 890-893. doi: 10.1038/ nature07769 PMID: 19225461
18. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J Cell Mol Med. 2008; 12: 2245-2254. doi: 10.1111/j.1582-4934.2008.00504.x PMID: 18798865
19. Fletcher LD, Bernfield L, Barniak V., Farley JE, Howell A, Knauf M, et al. Vaccine potential of the neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004; 72: 2088 Infection and Immunity-2100. PMID: 15039331
20. Masignani V, Comanducci M, Giuliani M.M., Bambini S., Adu-Bobie J, Aricò B, et al. Vaccination against neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003; 197: 789-799. PMID: 12642606
21. Ladhani SN, Cordery R, Mandal S., Christensen H, Campbell H, Borrow R., et al. Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease: Benefits of offering vaccination in addition to antibiotic chemoprophylaxis to close contacts of cases in the household, educational setting, clusters and the wider community. 2014; Available: https://www.gov.uk/government/publications/invasive-meningococcus-capsular-group-b-menb-preventing-secondary-cases
22. Joint Committee on Vaccination and Immunisation. JCVI position statement on use of Bexsero meningococcal B vaccine in the UK. 2014; Available: https://www.gov.uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement
23. Pajon R, Beernink PT, Harrison L.H., Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010; 28: 2122-2129. doi: 10.1016/j.vaccine.2009.12.027 PMID: 20044056
24. Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology. 2009; 155: 2873-2883. doi: 10.1099/mic.0.029876-0 PMID: 19574307
25. Piet JR, Brouwer MC, Exley R, van der Veen S, van de Beek D, van der Ende A. Meningococcal factor H binding protein fHbpd184 polymorphism influences clinical course of meningococcal meningitis. PLoSOne. 2012; 7: e47973. doi: 10.1371/journal.pone.0047973 PMID: 23110143
26. Brouwer MC, Read RC, van de Beek D. Host genetics and outcome in meningococcal disease: A systematic review and meta-analysis. Lancet Infect Dis. 2010; 10: 262-274. doi: 10.1016/S1473-3099(10)70045-1 PMID: 20334849
27. Brouwer MC, de Gans J, Heckenberg SG, Zwinderman A.H., van der Poll T, van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: A systematic review and meta-analysis. Lancet Infect Dis. 2009; 9: 31-44. doi: 10.1016/S1473-3099(08)70261-5 PMID: 19036641
28. Dale AP, Read RC. Genetic susceptibility to meningococcal infection. Expert Rev Anti Infect Ther. 2013; 11:187-199. doi: 10.1586/eri.12.161 PMID: 23409824
29. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010; 23: 740-780. doi: 10.1128/CMR.00048-09 PMID: 20930072
30. Johansson L, Rytkonen A, Bergman P., Albiger B, Kallstrom H, Hokfelt T., et al. CD46 in meningococcal disease. Science. 2003; 301: 373-375. PMID: 12869763
31. Källström H, Liszewski MK, Atkinson JP, Jonsson A. Membrane cofactor protein (MCPorCD46) is a cellular pilus receptor for pathogenic neisseria. Mol Microbiol. 1997; 25: 639-647. PMID: 9379894
32. Jarva H, Ram S, Vogel U., Blom AM, Meri S. Binding of the complement inhibitor C4bp to serogroup B neisseria meningitidis. J Immunol. 2005; 174: 6299-6307. PMID: 15879129
33. Bradley DT, Bourke TW, Fairley D.J., Borrow R., Shields MD, Young IS, et al. Genetic susceptibility to invasive meningococcal disease: MBL2 structural polymorphisms revisited in a large case-control study and a systematic review. Int J Immunogenet. 2012; 39: 328-337. doi: 10.1111/j.1744-313X.2012. 01095.x PMID: 22296677
34. Phillips C, Salas A, Sanchez J.J., Fondevila M., Gomez-Tato A, Alvarez-Dios J, et al. Inferring ancestral origin using a single multiplex assay of ancestry-informative marker SNPs. Forensic Sci Int Genet. 2007; 1: 273-280. doi: 10.1016/j.fsigen.2007.06.008 PMID: 19083773
35. Guiver M, Borrow R, Marsh J., Gray SJ, Kaczmarski EB, Howells D, et al. Evaluation of the applied bio-systems automated taqman polymerase chain reaction system for the detection of meningococcal DNA. FEMS Immunol Med Microbiol. 2000; 28:173-179. PMID: 10799809
36. Darton T, Guiver M, Naylor S., Jack DL, Kaczmarski EB, Borrow R, et al. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis. 2009; 48: 587-594. doi: 10.1086/596707 PMID: 19191644
37. Hackett SJ, Guiver M, Marsh J., Sills JA, Thomson APJ, Kaczmarski EB, et al. Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child. 2002; 86: 44-46. PMID: 11806883
38. Hughes AE, Orr N, Patterson C., Esfandiary H, Hogg R, McConnell V., et al. Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking. PLoS Med. 2007; 4: e355. PMID: 18162041
39. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of hardy-weinberg equilibrium. Am J Hum Genet. 2005; 76: 887-893. PMID: 15789306
40. Purcell S. PLINK. 2009; v1.07.
41. Purcell S, Neale B, Todd-Brown K, Thomas L., Ferreira MA, Bender D, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81: 559-575. PMID: 17701901
42. Tedesco F. Inherited complement deficiencies and bacterial infections. Vaccine. 2008; 26:I3-I8. PMID: 19388157
43. Costa I, Pajon R, Granoff DM. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. MBio. 2014; 5: e01625-14. doi: 10.1128/ mBio.01625-14 PMID: 25161192
44. Prymula R, Esposito S, Zuccotti G.V., Xie F., Toneatto D, Kohl I, et al. A phase 2 randomised controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB. Hum Vaccin Immun-other. 2014; 10: 2005-2014. doi: 10.4161/hv.29218 PMID: 25424810